Roche: FDA approves Avastin for advanced ovarian cancer
(CercleFinance.com) - US health regulators have approved Roche's blockbuster cancer drug Avastin as a treatment for women with advanced ovarian cancer following initial surgery.
The Food and Drug Administration (FDA) has approved Avastin in combination with chemotherapy, followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.
The approval was based on a phase III study in 1,873 women that has showed a median progression-free survival of 18.2 months, compared to 12 months in women who received chemotherapy alone.
Avastin is now approved for ten distinct uses across six different types of cancer in the United States.
This morning, Roche also said that it would present new phase III data on Ocrevus at the upcoming congress of the European Academy of Neurology, showing that the drug may provide meaningful benefits, such as a delay in the need for a wheelchair for people with primary progressive multiple sclerosis.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Food and Drug Administration (FDA) has approved Avastin in combination with chemotherapy, followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.
The approval was based on a phase III study in 1,873 women that has showed a median progression-free survival of 18.2 months, compared to 12 months in women who received chemotherapy alone.
Avastin is now approved for ten distinct uses across six different types of cancer in the United States.
This morning, Roche also said that it would present new phase III data on Ocrevus at the upcoming congress of the European Academy of Neurology, showing that the drug may provide meaningful benefits, such as a delay in the need for a wheelchair for people with primary progressive multiple sclerosis.
Copyright (c) 2018 CercleFinance.com. All rights reserved.